Response to Azacytidine in a Patient With Refractory Peripheral T-cell Lymphoma With TET2 Mutation

TL;DR

A patient with a rare and aggressive lymphoma subtype responded well to azacytidine after failing other treatments, suggesting potential for epigenetic therapies.

Contribution

Demonstrates successful treatment with azacytidine in refractory PTCL-NOS linked to a TET2 mutation.

Findings

A patient with refractory PTCL-NOS achieved a positive response to azacytidine.

The treatment decision was based on the presence of a TET2 mutation.

This case highlights the potential of epigenetic therapies in PTCL.

Abstract

Peripheral T-cell lymphomas (PTCLs) are an aggressive form of non-Hodgkin lymphomas. PTCLs have multiple subtypes, with PTCL not otherwise specified (PTCL-NOS) being the most common. This subtype usually has a high rate of relapse. Making an accurate diagnosis requires molecular genetic analyses, histopathological examination, and immunophenotyping. Treatment for PTCL traditionally starts with the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, and prednisone). We present a case of a patient with PTCL-NOS who progressed despite multiple treatment regimens, including both traditional and novel therapeutic agents, and finally achieved good results with azacytidine, selected based on a TET2 mutation. This case proposes future research into Azacytidine’s efficacy in this patient population and further exploration of the broader utility of epigenetic therapies in PTCL.

Figures